Healthcare

March 18, 2019

1

Boehringer Ingelheim announces FDA and EMA regulatory submission for nintedanib in systemic sclerosis associated ILD

  • Systemic sclerosis (SSc), also known as scleroderma, is a rare chronic connective tissue disease
  • Pulmonary fibrosis, or fibrosing interstitial lung disease (ILD), is a key driver of mortality in people living with SSc and constitutes a high unmet need1,2
  • Improving the lives of people living with pulmonary fibrosis is a key focus for Boehringer Ingelheim

(AETOS Wire) --"...

Continue Reading >

March 17, 2019

2

NMC Wins ‘UAE Deal of the Year’

NMC, the largest private healthcare provider in the Middle East, was presented with the ‘UAE Deal of the Year’ award for their five-year USD$400m Sukuk transaction at the Islamic Finance News (IFN) Awards 2019.

Commenting on the win, Prasanth Manghat CEO of NMC Healthcare, said: “I am very pleased to accept the UAE Deal of the Year Award; this would not have been possible without the trust and faith investors have shown in us.”

"...

Continue Reading >

March 17, 2019

3

Octapharma Group Reports Strong Results for 2018

  • Reporting revenue of €1.8 billion and operating income of €346 million
  • Group sales increased 4.5% compared to 2017 (on a constant currency basis, the growth rate is 6.6%)
  • All our products performed well, but to be highlighted are the year-on-year growth of our immunglobulin product portfolio, as well as Nuwiq® and fibryga®

(AETOS Wire) -- Commenting on the Group’s results, Octapharma CEO and Chairman Wolfgang Marguerre"...

Continue Reading >

March 12, 2019

4

Dental Monitoring Partners with Vitruvian to Accelerate Global Expansion of Its Innovative AI Solutions

(AETOS Wire)-- Dental Monitoring (“DM”), provider of the premier suite of Artificial Intelligence solutions in dentistry and orthodontics, has closed a funding round of €45 million, backed by leading growth investor Vitruvian Partners, to accelerate its global expansion.

Philippe SALAH, CEO of Dental Monitoring, said: At Dental Monitoring, we believe that the dental ecosystem can greatly"...

Continue Reading >

March 11, 2019

5

Celgene Submits Application to EMA for Ozanimod for the Treatment of Relapsing-Remitting Multiple Sclerosis

(AETOS Wire) -- Celgene Corporation (NASDAQ:CELG) today announced that the Company has submitted a Marketing Authorization Application to the European Medicines Agency (EMA) for ozanimod for the treatment of adults with relapsing-remitting multiple sclerosis (RRMS). Ozanimod is an oral, sphingosine 1-phosphate (S1P) receptor modulator, which binds with high affinity selectively to S1P subtypes 1 (S1P1) and 5 (S1P5).

The"...

Continue Reading >

March 11, 2019

6

‘My Clinic’ Bags Two Global Healthcare Awards

My Clinic’, one of the leading healthcare companies in Saudi Arabia with a major focus on the healthcare industry, has been recognized for its exceptional performance, prestigious achievements and rapid growth in healthcare, taking home two International Finance Magazine awards for 2018.

Up against stiff competition, ‘My Clinic’ won the awards for the “Best New"...

Continue Reading >

March 9, 2019

7

Vedolizumab (Entyvio®) Achieves Superior Rates of Clinical Remission vs. Adalimumab (Humira®) in First Ever Head-to-Head Biologic Clinical Study in Ulcerative Colitis

(AETOS Wire)-- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced results from the Phase 3b head-to-head VARSITY study which demonstrated that the gut-selective biologic vedolizumab (Entyvio®) was superior to the anti-tumor necrosis factor-alpha (anti-TNFα) biologic adalimumab (Humira®) in achieving clinical remission* in patients with moderately to severely active ulcerative colitis at week 52. Data showed that 31.3% (n=120/383) of patients receiving vedolizumab intravenous (IV) achieved the primary endpoint of clinical remission compared to 22.5% (n=87/386) of patients treated with adalimumab subcutaneous (SC) at week 52, with the difference being statistically significant (p=0.0061). These results were announced as an oral presentation (OP34) on Saturday March 9, 2019 from 09:40-09:50, at the 14th Congress of the European Crohn’s......

Continue Reading >

March 9, 2019

8

ResMed Acquires HB Healthcare to Help Millions of Koreans Living with Sleep Apnea, Other Respiratory Conditions

(AETOS Wire)-- ResMed (NYSE: RMD, ASX: RMD), a global leader in cloud-connected sleep and respiratory care devices in more than 120 countries, today announced that is has completed the acquisition of HB Healthcare (HBH) to help millions of South Koreans living with sleep apnea, chronic obstructive pulmonary disease (COPD) and other respiratory conditions.

HBH, a fast-growing privately owned South Korean home"...

Continue Reading >

March 9, 2019

9

Carestream Health to Sell Its Healthcare IT Business to Philips

(AETOS Wire)-- Carestream Health has signed an agreement with Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, to sell its healthcare information systems (HCIS) business to Philips.

Carestream’s HCIS business unit provides imaging IT solutions to multi-site hospitals, radiology services providers, imaging centers and specialty medical clinics around the world. The business"...

Continue Reading >

March 7, 2019

10

Boehringer Ingelheim's novel antibody shows potential to transform treatment of rare form of psoriasis

(AETOS Wire)-- The New England Journal of Medicine (NEJM) today published new data from a Phase I clinical trial showing BI 655130, a first-in-class investigational treatment, significantly improved symptoms of generalised pustular psoriasis (GPP), a rare form of psoriasis.1

BI 655130 is a monoclonal antibody that blocks the action of the interleukin-36 receptor (IL-36R), a signalling pathway within the immune"...

Continue Reading >


Forex News Headline



Forex Market Video